Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide in Dominant Optic Atrophy OPA1
NCT06007391Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nicotinamide in dominant optic atrophy (DOA), sponsored by Centre Hospitalier Universitaire d'Angers. Started Jan 2024; status: active, not recruiting.
02
Drugs
nicotinamide
03
Conditions
dominant optic atrophy (DOA)
Beyond the preview
Go deeper on NCT06007391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007391.